Status:
COMPLETED
Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-45 years
Brief Summary
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (...
Detailed Description
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of di...
Eligibility Criteria
Inclusion
- Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are "having difficulty paying the bills no matter what they do" to a question about their current household financial situation.18, 19
- report a history of Stage 1-3 breast cancer
- reports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET)
- not in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin
- at least 3 months, but no more than 3 years out of completion of active treatment
- no evidence of recurrent/metastatic disease
- at least 18, but\< 45 years of age at diagnosis of first invasive breast cancer
- English or Spanish speaking
- are willing to consent to the interview
Exclusion
- HR- breast cancer and indicate they are not taking ET
- HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET
- Stage 0 (DCIS) breast cancer
- Recurrent or metastatic disease
- Less than 3 months or more than 3 years post-active treatment
- Less than 18 years old or ≥45 years old at diagnosis
Key Trial Info
Start Date :
March 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2018
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03447886
Start Date
March 9 2018
End Date
August 27 2018
Last Update
June 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215